Liangyou Gu

Abstract Sunitinib resistance poses a significant challenge in the management of advanced and metastatic clear cell renal cell carcinoma (ccRCC). Although RNA-binding proteins (RBPs) have recently emerged as important regulators of tumorigenesis, their roles in ccRCC progression and sunitinib resistance remain poorly understood. Through comprehensive bioinformatics analysis of clinical datasets, we identified PABPC1 as an RBP significantly upregulated in ccRCC.

Abstract The combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has improved clinical outcomes in advanced renal cell carcinoma (aRCC), though therapeutic resistance remains a major challenge. We conducted single-cell transcriptomic analysis on 61 tumor samples from 34 aRCC patients treated with TKIs alone or in combination with ICIs. Non-responders exhibited increased neutrophil infiltration and enrichment of SAA+ tumor cells following treatment.

1 INTRODUCTION Angiomyolipomas (AML) is a benign mesenchymal tumor consisting of aberrant thick-walled blood vessels, smooth muscle cells, and adipose tissue.1 AML can arise on its own or, in many cases, in association with the tuberous sclerosis complex (TSC).